Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model

Journal of Psychopharmacology

Volumn 24, Issue 3, 2010, Pages 383-388

  Van Dam, D ^b   Coen, K ^b   De Deyn, P P ^a,b  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; App23 transgenic mouse model; Cognition; Diseasemodifying therapy; Ibuprofen; Morris water maze

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SODIUM CHLORIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; HETEROZYGOSITY; IN VITRO STUDY; IN VIVO STUDY; LEARNING; MALE; MEDICAL RESEARCH; MOUSE; NONHUMAN; OSMOTIC PUMP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RISK REDUCTION; SENILE PLAQUE; SPATIAL DISCRIMINATION; TASK PERFORMANCE; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISCRIMINATION; AGING; ANIMAL; C57BL MOUSE; DISEASE COURSE; DRUG EFFECT; INFUSION PUMP; MAZE TEST; PSYCHOLOGICAL ASPECT; RANDOMIZATION;

AGING; ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IBUPROFEN; INFUSION PUMPS, IMPLANTABLE; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RANDOM ALLOCATION;

EID: 77953060906     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108097630     Document Type: Article

References (34)

1. Aisen, PS, Davis, KL, Berg, JD, Schafer, K, Campbell, K, Thomas, RG, et al. (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54: 588-593. (Pubitemid 30082922)
2. Akiyama, H, Barger, S, Barnum, S, Bradt, B, Bauer, J, Cole, GM, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
3. Berezovska, O, Lleo, A, Herl, LD, Frosch, MP, Stern, EA, Bacskai, BJ, et al. (2005) Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 25: 3009-3017. (Pubitemid 40389259)
4. Bodick, N, Forette, F, Hadler, D, Harvey, RJ, Leber, P, McKeith, IG, et al. (1997) Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord 11: 50-53.
5. Eriksen, JL, Sagi, SA, Smith, TE, Weggen, S, Das, P, McLendon, DC, et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112: 440-449. (Pubitemid 38063773)
6. Gasparini, L, Ongini, E, Wenk, G (2004) Non-steroidal antiinflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 91: 521-536. (Pubitemid 39431148)
7. Hirohata, M, Ono, K, Naiki, H, Yamada, M (2005) Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 49: 1088-1099. (Pubitemid 41503307)
8. Jantzen, PT, Connor, KE, DiCarlo, G, Wenk, GL, Wallace, JL, Rojiani, AM, et al. (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22: 2246-2254. (Pubitemid 35386524)
9. Kelly, PH, Bondolfi, L, Hunziker, D, Schlecht, HP, Carver, K, Maguire, E, et al. (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24: 365-378. (Pubitemid 36005416)
10. Kotilinek, LA, Westerman, MA, Wang, Q, Panizzon, K, Lim, GP, Simonyi, A, et al. (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131: 651-664.
11. Kuo, YM, Beach, TG, Sue, LI, Scott, S, Layne, KJ, Kokjohn, TA, et al. (2001) The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol Med 7: 609-618. (Pubitemid 34175289)
12. Lalonde, R, Dumont, M, Staufenbiel, M, Sturchler-Pierrat, C, Strazielle, C (2002) Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res 956: 36-44. (Pubitemid 35335554)
13. Lim, GP, Yang, F, Chu, T, Chen, P, Beech, W, Teter, B, et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 5709-5714. (Pubitemid 30636898)
14. Lim, GP, Yang, F, Chu, T, Gahtan, E, Ubeda, O, Beech, W, et al. (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22: 983-991. (Pubitemid 34066567)
15. Lleó, A, Berezovska, O, Herl, L, Raju, S, Deng, A, Bacskai, BJ, et al. (2004) Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 10: 1065-1066. (Pubitemid 39424866)
16. Mori, E, Hashimoto, M, Krishnan, KR, Doraiswamy, PM (2006) What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 20: S19-S26.
17. Sastre, M, Dewachter, I, Landreth, GE, Willson, TM, Klockgether, T, van Leuven, F, et al. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23: 9796-9804. (Pubitemid 37371592)
18. Sturchler-Pierrat, C, Abramowski, D, Duke, M, Wiederhold, KH, Mistl, C, Rothacher, S, et al. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292. (Pubitemid 27518514)
19. Sturchler-Pierrat, C, Staufenbiel, M (2000) Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci 920: 134-139. (Pubitemid 32056562)
20. Van Dam, D, Abramowski, D, Staufenbiel, M, De Deyn, PP (2005) Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180: 177-190. (Pubitemid 40897084)
21. Van Dam, D, Coen, K, De Deyn, PP (2008) Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology (Berl) 197: 37-43. (Pubitemid 351961810)
22. Van Dam, D, D'Hooge, R, Staufenbiel, M, Van Ginneken, C, Van Meir, F, De Deyn, PP (2003) Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17: 388-396. (Pubitemid 36459519)
23. Van Dam, D, De Deyn, PP (2006a) Cognitive evaluation of diseasemodifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16: 59-69. (Pubitemid 43005096)
24. Van Dam, D, De Deyn, PP (2006b) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5: 956-970. (Pubitemid 44660608)
25. Van Gool, WA, Weinstein, HC, Scheltens, P, Walstra, GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455-460. (Pubitemid 32769852)
26. Vloeberghs, E, Coen, K, Van Dam, D, De Deyn, PP (2008) Validation of the APP23 mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. Arzneimittelforschung / Drug Res 58: 265-268. (Pubitemid 351961810)
27. Vloeberghs, E, Van Dam, D, Coen, K, Staufenbiel, M, De Deyn, PP (2006) Aggressive male APP23 mice modeling behavioral alterations in dementia. Behav Neurosci 120: 1380-1383. (Pubitemid 46058713)
28. Vloeberghs, E, Van Dam, D, Engelborghs, S, Nagels, G, Staufenbiel, M, De Deyn, PP (2004) Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci 20: 2757-2766. (Pubitemid 39573791)
29. Vloeberghs, E, Van Dam, D, Franck, F, Staufenbiel, M, De Deyn, PP (2007b) Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behav Brain Res 180: 146-151. (Pubitemid 46729569)
30. Weggen, S, Eriksen, JL, Das, P, Sagi, SA, Pietrzik, CU, Findlay, KA, et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216. (Pubitemid 33051236)
31. Weggen, S, Rogers, M, Eriksen, J (2007) NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 28: 536-543.
32. Yan, Q, Zhang, J, Liu, H, Babu-Khan, S, Vassar, R, Biere, AL, et al. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504-7509. (Pubitemid 37034066)
33. Zandi, PP, Breitner, JC (2001) Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 22: 811-817.
34. Zhou, Y, Su, Y, Li, B, Liu, F, Ryder, JW, Wu, X, et al. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302: 1215-1217. (Pubitemid 37421027)